Dynamically expressed microRNA-15b modulates the activities of CD8+ T lymphocytes in mice with Lewis lung carcinoma by Guocheng Zhong et al.
Zhong et al. Journal of Translational Medicine 2013, 11:71
http://www.translational-medicine.com/content/11/1/71RESEARCH Open AccessDynamically expressed microRNA-15b modulates
the activities of CD8+ T lymphocytes in mice with
Lewis lung carcinoma
Guocheng Zhong1, Xiaoming Cheng2, Haixia Long1, Luhang He1, Wei Qi1, Tong Xiang1, Zhongquan Zhao1
and Bo Zhu1*Abstract
Background: CD8+ T cells are key members of adaptive immunity against tumorigenesis. As subset of CD8+ T
cells, effector T cells (Te) and memory T cells (Tm) have different biological activities. The former can kill tumor cells
but come into apoptosis in a certain period and the latter is static with the ability of self-renewal. Previous studies
showed that microRNAs (miRNA) played critical roles in regulating adaptive immunity. This study aimed to identify
the different expression of miRNAs between Te and Tm cells in tumor-bearing mice and to sort out the target
miRNAs which can be regulated to improve anti-tumor activities of CD8+ T cells.
Methods: miRNA expression profiling was performed on CD8+ Te and Tm cells from mice with Lewis lung
carcinoma. Differentially expressed miRNA (miRNA-15b) was chosen and analyzed by qRT-PCR. Then, flow
cytometry, ELISA, and CFSE kit were used to evaluate the biological effects of miRNA-15b on apoptosis, cytokine
secretion, phenotype, and proliferation of CD8+ T cell. The possible downstream target genes of this miRNA were
also analyzed.
Results: Analysis of miRNA microarray and qRT-PCR showed that the level of miRNA-15b was higher in CD8+ Tm
cells than in Te cells. Higher expression of miRNA-15b was observed in CD8+ T cells from tumor-bearing mice than
those from healthy ones. Transfection of CD8+ T cells with miRNA-15b mimics could prevent T cells from apoptosis
by inhibiting the translation of DEDD (Death Effector Domain-containing DNA binding protein). Moreover, ectopic
miRNA-15b could inhibit the activation of CD8+ T cells (via repressing the production of IL-2 and IFN-γ and
expression of CD69) and promote expression of CD44 through unknown pathways.
Conclusion: Up-regulation of miRNA-15b in tumor environment might negatively regulate anti-tumor immunity
through inhibiting function of CD8+ T cells. miRNA-15b might be a potential therapeutic target for immunotherapy.
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Cancer is a lethal disease with severe functional deterio-
ration and high mortality. Currently, T cells, particularly
CD8+ T cells have been widely employed as effector cells
in anti-tumor immunotherapy [1,2]. However, the cli-
nical efficacy of T cell immunotherapy is very limited be-
cause of the short lifetime of effector T cells due to their
susceptibility to apoptosis in vivo. In addition, anti-* Correspondence: oncology_bozhu@yahoo.com.cn
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reproduction in any medium, provided the ortumor activities of T cells are frequently impaired by
powerful tumor microenvironments [3]. Therefore, it
has attracted many researchers to explore the biological
activity of T cells.
During a special cellular immune response, naive T
cells activated by antigen would differentiate to effector
T (Te) cells with various immune functions. As antigen
is cleared, over 95% of Te cells becomes self-apoptotic,
and less than 5% of Te cells sequentially differentiates to
memory T (Tm) cells which can survive and self-renew
in lymphoid tissue for a long term [4]. Is there any regu-
latory difference which exists between Te and Tm cells?Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hance anti-tumor ability of T cells [5]?
Numerous aspects involving including antigenic
stimulation signal, T cell microenvironment, cytokine
productions, and T cell surface molecules [6-8] have
been investigated. More recently, microRNAs (miRNA),
which participate in immunological regulation, have
attracted much attention [9]. miRNAs are non-coding
small molecule RNA of about 22 nucleotides and can
degrade target mRNAs or inhibit their translation. Cellu-
lar proliferation, differentiation, growth, metabolism and
many other biological processes are influenced by
miRNAs [10,11]. Substantial studies have shown that the
miRNAs are involved in subtle or accurate regulation of
T cells [12,13]. So far, related researches mainly concen-
trate on the miRNAs that regulate CD4+ T cells, such as
miRNA-146a [14], miRNA-155 [15], miRNA-17~92 [16].
Very few miRNAs that regulate CD8+ T cells have been
reported. In this study, we performed the miRNA micro-
array analysis on differential expression between CD8+
Te and Tm cells from mice with Lewis lung carcinoma
(Additional file 1: Table S1) and identified the target
miRNAs differentially expressing in T cell subsets (Te
and Tm cells). Among the miRNAs whose expression in
Tm was higher than in Te, the level of miRNA-15b was
higher in CD8+ T cells from tumor-burdened mice than
those from healthy mice. The effects of miRNA-15b on
apoptosis, phenotype, cytokine secretion and prolifera-
tion of CD8+ T cells were studied and the possible target
genes of miRNA-15b also analyzed.
Materials and methods
Establishment of tumor-burdened mice model
The Lewis lung carcinoma cell line was purchased from
ATCC (American Type Culture Collection). Female
C57BL/6 mice (4–6 weeks old) were obtained from the
Chinese Academy of Medical Sciences (Beijing, China).
All mice were fed with irradiated food and were exe-
cuted by cervical dislocation. Lewis lung carcinoma cells
in growth logarithm period were re-suspended in
phosphate-buffered saline (PBS). 1 × 105 cells were
injected into the armpit and groin regions of C57 BL/6
mice respectively. These tumor-burdened mice were
continually raised to 4–5 weeks until the tumors grew
up to about 3 × 3 cm (Additional file 2: Figure S1). The
ethical approval of animal experiment was authorized by
Third Military Medical University and all mice Animals
were handled following an Institutional Animal Care
and Use Committee-approved protocol.
Isolation of effector CD8+ Te cells and CD8+ Tm cells
from tumor-burdened mice
4–5 weeks after injection of Lewis lung carcinoma cells
into C57 BL/6, CD8+ Te and CD8+ Tm cells wereisolated, purified and pooled from the spleens of 10 tumor-
burdened mice by fluorescence-based cell sorting [17]. The
purity of Tm (CD8+CD44+CD197+) and Te (CD8+CD44-
CD69+) was more than 90%. All fluorescence antibodies
(CD8-FITC/CD44-PE/CD69-APC/CD197-APC monoclo-
nal antibodies) were purchased from BD Pharmingen™ or
BioLegend.
Cell culture, co-stimulation and activation
CD8+ T cells from spleens of tumor-burdened mice or
healthy ones were isolated by positive selection with anti-
CD8 magnetic beads (Order No. 130-049-401, Miltenyi
Biotec) and were adjusted to 1 × 106 cells/ml in RPMI
(Roswell Park Memorial Institute)-1640 supplemented
with L-glutamine, penicillin-streptomycin, sodium pyru-
vate (Hyclone), nonessential amino acids (Invitrogen) and
10% FCS (Hyclone). For activation of CD8+ T cells, mono-
clonal anti-CD3 antibody (CD3 mAb) at a final concentra-
tion of 2.5 μg/mL (145-2C11, eBiosicence) was placed into
96-well plates and incubated at 4°C for 8-10 h. Then, the
medium of CD3 mAb was removed carefully and the
plates were washed twice with PBS followed by placing
CD8+ T cells into the plates (100μL cells per well). Then,
the CD8+ T cells were co-stimulated with CD28 mAb at a
final concentration of 2 μg/mL (35.71, eBiosicence) in
combination with CD3 mAb for 24 to 120 h at 37°C and
5% CO2 [18].
RNA extraction, miRNA microarray and quantitative
real-time PCR
Total RNA of CD8+ Te or Tm cells were prepared with
TRIzol (Invitrogen) and extracted for miRNA microarray
analysis or quantitative real-time PCR assay (total RNA
of CD8+ T cells from tumor-burdened mice or healthy
mice were prepared similarly). miRNA microarray expe-
riments were performed using Affymetrix Genechip
miRNA 2.0 Array (miRNA QC tool version 1.1.1 or
“AffyMir” version 1.1.1 was used for data analysis). For
miRNA quantitative reverse-transcribed PCR (qRT-
PCR), extracted total RNA was reverse-transcribed with
specific primer of miRNA-15b (RIBOBIO, Guangzhou,
China) by using the PrimeScriptR RT reagent Kit with
gDNA Eraser (TaKaRa, Japan) on an ABI PRISM 7500
Real-Time PCR system (Applied Biosciences, Benicia,
CA, USA). qRT-PCR of miRNA-15b was performed at
the following conditions: 95°C 30 s, followed by 40 cycles
at 95°C for 5 s, 60°C for 34 s and 70°C for 45 s. U6 gene
was used as a normalization control.
Transfection of miRNA-mimics
Fresh CD8+ T cells (1 × 106/mL) from spleen of tumor-
burdened mice were transfected with 50nM miRNA-15b
mimics (mimic-15b) or negative-control scrambled miRNA
mimics (mimic-NC, RIBOBIO) using Lipofectamine™ 2000
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31085–062, Invitrogen) following the manufacturer’s proto-
col [19]. The transfection rate of T cells was measured by
flow cytometry or qRT-PCR 12 h later.
Assay of apoptosis
CD8+ T cells transfected with mimic-15b or mimic-NC
(5 × 105 cells/mL) were grown in RPMI-1640. The apop-
tosis of these T cells were induced by CD3 mAb (5 μg/mL,
clone 145-2C11) for 12 h. Apoptotic cell fractions were
identified by double staining of annexin V–fluorescein
isothiocyanate (FITC) and propidium iodide (PI) using
an apoptosis detection kit (K101-25, BioVision) according
to the manufacturer’s instructions. Apoptotic cells were
analyzed by flow cytometry.
ELISA
CD8+ T cells from spleens of tumor-burdened mice
were transfected with mimic-15b or mimic-NC and were
co-activated by CD3/CD28 mAb. The culture super-
natant was then collected, and the IL-2 and IFN-γ in
supernatant were detected with ELISA kits (EK0398,
EK0375, Boster) according to the manufacturer’s instruc-
tions [20]. Plates were read at an absorbance of 450 nm
(A450) using a Sunrise microplate reader. IL-2 and IFN-
γ were tested in quadruplicates in three independent
ELISA measurements.
Flow cytometry
Transfected CD8+ T cells with mimic-15b or mimic-NC
were co-activated respectively, as described above. Before
and 48–120 h after activation, The transfected CD8+ T
cells were stained with APC-labeled CD69 mAb, PE-
labeled CD44 mAb or amouse isotype control (BD
Pharmingen™) at 4°C for 30 min and the expression of
CD69 or CD44 in CD8+ T cells was determined by flow
cytometry.
Cell proliferation assay
To detect proliferation rate, CD8+ T cells transfected
with mimic-15b or mimic-NC were labeled with 0.6 mM
Carboxyfluorescein Diacetate (CFSE) dye (CellTrace™
CFSE Cell Proliferation Kit, C34554, Invitrogen) for
10 min at 37°C and the staining was ended by adding 5
volumes of ice-cold culture media to the cells. Labeled
CD8+ T cells were co-activated for 96 h. Cell prolifera-
tion was then assessed by flow cytometry and analyzed
by FlowJo software version 6.3 [21].
Luciferase reporter experiments
To confirm target genes of miRNA-15b, we performed
luciferase reporter assays on DNA constructs (based on
pGL-3-luc vector, Promega) containing the firefly luci-
ferase gene, which was linked to the 3-untranslatedregion (UTR) of each potential target including wild type
or mutants (bases 2–6 in the seed region where miRNA-
15b bind to target gene’ 3-UTR were mutated). The re-
porter constructs were transiently co-transfected in
293T cells with mimic-15b or mimic-NC, then, the luci-
ferase activity was measured using the Dual-Luciferase
assay kit (Promega) according to manufacturer’s instruc-
tions. Renilla luciferase reporter was used to normalize
firefly luciferase readings.
Detection of target gene by qRT-PCR and Western blot
mRNA of DEDD and a normalization control of β-actin





ACA-30 (RIBOBIO). RNA extraction and qRT-PCR were
performed as mentioned above. PCR were carried out
for 35 cycles at 94°C for 30 s, 69°C for 30 s and 74°C for
60 s. Relative expression level was calculated with Com-
parative Ct method.
For Western blots, a specific mAb of DEDD (G6) was
used (sc-271191, Santa cruz biotechnology). Mouse mAb
β-actin (C4) was used to detect β-actin as loading con-
trol (sc-47778, Santa cruz biotechnology). CD8+ T cells
were lysed, and extracted proteins were separated with
polyacrylamide gel electrophoresis. After that, proteins
were transferred onto a polyvinylidene difluoride mem-
brane (Millipore). Membranes were washed with Tris
buffered saline Tween (TBST), blocked in 5% non-fat
dry milk [22], and blotted with DEDD (1:250) or β-actin
(1:1,000) antibodies. The image was quantified using
Image J software version 10.2.
Statistical analysis
All data were analyzed by SAS (Statistical Analysis Sys-
tem) software. The statistical significance of differences
was determined with student t-test for pairwise compari-
son. The difference between 2 groups was considered
significant when P < 0.05.
Results
miRNA-15b was upregulated in CD8+ Tm from
tumor-burdened mice
Results from the miRNA microarray displayed that 25
miRNAs were differentially expressed in CD8+ Tm and
Te cells (Figure 1A). 9 miRNAs were down-regulated
and 15 miRNAs were up-regulated in Tm cells, com-
pared with Te cells (Table 1). As shown in Figures 1B
and C, miRNA-15b was one of the miRNAs that had
higher levels in CD8+ Tm, consistent with a previous
study [23]. The data were confirmed by qRT-PCR
(Figure 2A). Further analysis indicated that the level
Figure 1 The expression of miRNA-15b between CD8+ effector T (Te) cells and memory T (Tm) cells from the spleens of tumor-
burdened mice. A) CD8+ Te cells labeled with CD8 + (FITC)CD44-(PE)CD69 + (APC) and CD8+ Tm cells labeled with CD8 + (FITC)CD44 + (PE)CD197 +
(APC) were purified by fluorescence-based cell sorting. B) Diagram shows the differentially expressed miRNAs between CD8+ Te and Tm cells. Each
row represents a single miRNA. Red color represents that the miRNA was highly expressed and green color represents low expression level. C) Main
miRNAs which were differentially expressed in CD8+ Te and Tm cells were listed. 9 of them were down-regulated and 15 of them were up-regulated
in Tm cells.
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tumor-burdened mice was also higher than those
from healthy ones (Figure 2B). The role of miRNA-
15b in regulating function of CD8+ T cells is not
reported previously. We then chose it for further
investigation.Expression of miRNA-15b was altered during T cell
activation and differentiation
To understand the roles of miRNA-15b in CD8+ T cell
activation and differentiation, we treated CD8+ T cells
with monoclonal antibodies against CD3 and CD28. As
shown in Figure 2C, the level of miRNA-15b was signifi-
cantly upregulated in non-activated CD8+ T cells and
progressively decreased upon CD3/CD28 co-stimulation.After 48 h, the expression of miRNA-15b was re-
elevated slowly.Transfection efficiency of CD8+ T cells
To investigate how miRNA-15b regulates functions
of CD8+ T cells, we synthesized miRNA-15b mimics
and labeled them with cy3 (mimic-15b-cy3). Then
CD8+ T cells were transfected with mimic-15b-cy3
[24]. Efficiency of transfection was determined by flow
cytometric analysis of positive cells with red fluores-
cence (cy3 display red fluorescence). The data showed
that about 45~55% CD8+ T cells were positive. qRT-
PCR analysis confirmed that miRNA-15b mimics were
successfully transfected into CD8+ T cells (Additional
file 3: Figure S2).
Table 1 The list of differentially expressed microRNAs between CD8+ Te and Tm cells
ProbeSet Name Mature1_Acc mirbaseV18 CD8+Te CD8+Tm Style Log2
mmu-miR-486_st MIMAT0003130 mmu-miR-486-5p 8.906548 5.336512 up 3.570036
mmu-miR-139-5p_st MIMAT0000656 mmu-miR-139-5p 7.818672 5.802054 up 2.016618
mmu-miR-30b_st MIMAT0000130 mmu-miR-30b-5p 7.390241 6.001204 up 1.389037
mmu-miR-106b_st MIMAT0000386 mmu-miR-106b-5p 9.228545 8.014892 up 1.213653
mmu-miR-27a_st MIMAT0000537 mmu-miR-27a-3p 8.051024 6.890368 up 1.160656
mmu-miR-30c_st MIMAT0000514 mmu-miR-30c-5p 8.109971 6.963645 up 1.146326
mmu-miR-15a_st MIMAT0000526 mmu-miR-15a-5p 6.800948 5.663513 up 1.137387
mmu-miR-690_st MIMAT0003469 mmu-miR-690 8.572385 7.465322 up 1.107063
mmu-miR-194_st MIMAT0000224 mmu-miR-194-5p 6.475734 5.470155 up 1.005579
mmu-miR-20b_st MIMAT0003187 mmu-miR-20b-5p 8.066008 9.086855 down −1.020847
mmu-miR-106a_st MIMAT0000385 mmu-miR-106a-5p 8.328273 9.380265 down −1.051992
mmu-miR-132_st MIMAT0000144 mmu-miR-132-3p 5.455552 6.673903 down −1.218351
mmu-miR-466f_st MIMAT0005844 mmu-miR-466f 5.642788 6.931221 down −1.288433
mmu-miR-182_st MIMAT0000211 mmu-miR-182-5p 4.408060 5.698591 down −1.290531
mmu-miR-466f-5p_st MIMAT0004881 mmu-miR-466f-5p 5.711618 7.241209 down −1.529591
mmu-miR-466j_st MIMAT0005848 mmu-miR-466j 5.609854 7.204075 down −1.594221
mmu-miR-15a-star_st MIMAT0004624 mmu-miR-15a-3p 4.456201 6.089243 down −1.633042
mmu-miR-31_st MIMAT0000538 mmu-miR-31-5p 4.899204 6.755762 down −1.856558
mmu-miR-574-5p_st MIMAT0004893 mmu-miR-574-5p 5.894817 7.919928 down −2.025111
mmu-miR-1187_st MIMAT0005837 mmu-miR-1187 5.847568 7.887634 down −2.040066
mmu-miR-16-star_st MIMAT0004625 mmu-miR-16-1-3p 5.524515 8.019949 down −2.495434
mmu-miR-15b_st MIMAT0000124 mmu-miR-15b-5p 6.722845 9.358693 down −2.630109
mmu-miR-34a_st MIMAT0000542 mmu-miR-34a-5p 4.728513 7.604746 down −2.876236
mmu-miR-155_st MIMAT0000165 mmu-miR-155-5p 7.589617 10.60282 down −3.013203
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activation-induced cell death (AICD)
Repetitive stimulation of TCR on T cells can lead to apop-
tosis of activated T cells. This process is mainly mediated
by AICD and FAS/FAS ligand system. This apoptosis can
be induced in vitro by ligation of TCR complex with the
anti-CD3 antibody [25]. Our data showed that the apop-
tosis in CD8+ T cells transfected with mimic-15b was less
than that in control T cells transfected with mimic-NC at
12 h after adding the anti-CD3 antibody, (Figures 3A and
B), indicating that miRNA-15b may be a negative regula-
tor of AICD.
MiRNA-15b inhibited the production of IL-2 and IFN-γ in
CD8+ T cells
To investigate whether miRNA-15b regulates the secre-
tion of IL-2 and IFN-γ, which are important for anti-
tumor immunity, CD8+ T cells transfected with mimic-
15b or mimic-NC were co-activated by the antibodies
against CD3 and CD28. Supernatants from the transfected
T cells were collected at 24 h and 48 h after co-activation
and production of IL-2 and IFN-γ was measured by
ELISA kit. As shown in Figures 3C and D, the secretion ofIL-2 and IFN-γ was significantly reduced in the T cells
transfected with mimic-15b upon co-stimulation, com-
pared with the T cells transfected with mimic-NC (P <
0.05). The results suggest that miRNA-15b may impair
the anti-tumor activities of CD8+ T cells [26].
MiRNA-15b regulated phenotype of CD8+ T cells but did
not affect proliferation of T cells
CD69 is a marker of activation of T cell and CD44 is de-
finitive indicator of memory cells. To investigate whether
miRNA-15b influences the phenotypes of T cells, the
levels of CD69 and CD44 in CD8+ T cells transfected
with mimic-15b or mimic-NC were measured after co-
stimulation [27]. The results showed that the expression
of CD69 in CD8+ T cells transfected with mimic-15b was
lower than that in control T cells transfected with mimic-
NC, while the expression of CD44 was higher in T cells
transfected with mimic-15b than in control T cells
(Figures 4A, B and C).
The effect of miRNA-15b on the proliferation of CD8+
T cells was determined at 96 h after co-stimulation with
the antibody against CD3 and CD28 using CFSE kit.
Figure 4D shows that there was no significant difference
Figure 2 Dynamic expression of miRNA-15b in CD8+ T cells was detected by qRT-PCR. A) The relative expression of miRNA-15b in CD8+
Te and Tm cells was detected by qRT-PCR. U6 was used as an internal control to normalize the relative amounts of miRNA-15b. *P < 0.01.
B) Relative expression of miRNA-15b was detected in CD8+ T cells from tumor-burdened mice or healthy ones by qRT-PCR. The results are
presented as mean ± standard deviation and obtained from 6 independent experiments (6 tumor-burdened mice vs 6 healthy mice). *P < 0.05.
C) CD8+ T Cells were co-stimulated by CD3/CD28 mAb and the levels of miRNA-15b were measured at different time points by qRT-PCR.
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control T cells (p > 0.05).
Prediction and validation of target genes of miRNA-15b
To reveal the biological relevance of miRNA-15b to the
functions of CD8+ T cells, such as activation, apoptosis,
or proliferation, we searched for the potential targets of
miRNA-15b by using bioinformatics tools (miRGen,
TargetScan and PicTar). The result showed that about
600 genes were predicted as the targets of miRNA-15b.
We selected 8 putative target genes, which are involved
in activities of T cells (Table 2 and Figure 5A). We
constructed the luciferase reporter constructs containing
the 3-untranslated region (UTR) of each potential target
genes, including CD28, TNF receptor-associated factor
3, DEDD, interleukin-1 receptor-associated kinase 2,
E2F transcription factor 3, programmed cell death 6
interacting protein, lipopolysaccharide-induced TNF fac-
tor and Interleukin-15. As demonstrated by luciferase
reporter assays, the transfection with mimic-15b signifi-
cantly reduced the luciferase activities of the reporter
gene fused to the DEDD 30UTR, but other potential tar-
gets were not affected by mimic-15b overexpression.Mutation of 4 nucleotides in the 30UTR seed sequence
of DEDD could reverse the inhibitory effect of mimic-
15b, indicating that the effect was specific (Figure 5B).
To further confirm that DEDD is regulated by miRNA-
15b, we transfected mice CD8+ T cells with mimic-15b
or mimic-NC. We observed that at 72 h after transfec-
tion, the levels of DEDD mRNA and protein in T cells
transfected with mimic-15b were significantly decreased
(Figures 5C and D). In addition, the protein level of
DEDD in Tm cells from tumor-burdened mice was
lower than that in Te cells (Figure 5E). There is no dif-
ference of the level of DEDD mRNA between Tm and
Te cells (p > 0.05, data not shown).
Discussion
It has been known that the differentiation and function
of T cells are accurately regulated by miRNAs [28,29].
Abnormality of this regulation is linked to immunodefi-
ciency and tumorigenesis [30]. On the other hand, being
one of T cell subsets, Te cells which decide the strength
and direction of a special anti-tumor immune response
have short survival time and Tm cells whose function is
relative static could exist over long periods in vivo. In
Figure 3 Ectopic expression of miRNA-15b protects CD8+ T cells from apoptosis and impedes the production of IL-2 and IFN-γ. A) 12 h
after adding the anti-CD3 antibody, flow cytometry showed that CD8+ T cells with mimic-15b (right) displayed less apoptosis than T cells with
mimic-NC (left). B) Apoptotic CD8+ T cells (which were labeled as annexin V-FITC positive) were evaluated. The result was derived from three
independent assays (mean ± standard deviation). *P < 0.01. C) CD8+ T cells transfected with mimic-15b or mimic-NC were co-stimulated with
CD3/CD28 mAb for 24 h and 48 h, IL-2 levels were determined by ELISA assay. Each value is the mean of 3 independent detections. *P < 0.01.
D) 24 h and 48 h after co-stimulation, IFN-γ levels were determined by ELISA assay. Each value was the mean of 3 independent detections. *P < 0.01.
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fluence the functions of CD8+ T cells and investigate the
possible mechanisms by which CD8+ T cells are
regulated.
In order to predict the potential miRNAs which were in-
volved in regulating differentiation of CD8+ T cells, espe-
cially in tumor-burdened environments, we established a
tumor-burdened mice model with Lewis lung carcinoma
and isolated the CD8+ Te and Tm cells [31]. The analysis
of miRNA microarray showed that the expression of
miRNA-15b was higher in CD8+ Tm cells than in Te cells
[32]. This result was verified by qRT-PCR. We found that
the level of miRNA-15b in CD8+ T cells from tumor-
burdened mice was also higher than those from healthy
ones, indicating that miRNA-15b may be involved in regu-
lating CD8+ T cells and influenced by tumor environment.
We noticed that co-stimulation with the anti-CD3 and
CD28 antibody remarkably repressed the expression of
miRNA-15b within 48 h, but the miRNA-15b level was re-
stored slowly later, suggesting that the fluctuation of thelevel of miRNA-15b may associate with the activation of
CD8+ T cells.
Compared with Te cells, Tm cells have more potent
anti-apoptotic ability. As the expression of miRNA-15b
was higher in Tm cells than in Te cells, we examined the
effect of miRNA-15b on survival of CD8+ T cells. Our
results showed that overexpression of miRNA-15b
prevented CD8+ T cells from apoptosis induced by the
anti-CD3 antibody, suggesting that miRNA-15b may affect
the survival of CD8+ T cells in tumor microenvironment.
In addition to apoptosis, we also tested other effects of
miRNA-15b on CD8+ T cells. We demonstrated that
overexpression of miRNA-15b in CD8+ T cells impaired
the production of IL-2 and IFN-γ in CD8+ T cells. Flow
cytometry analysis showed that miRNA-15b can inhibit
the expression of CD69, an early activation marker of T
cells and upregulate the expression of CD44, a memory
marker. These findings indicated that miRNA-15b may
play a negative role in activation of CD8+ T cell and in-
duce T cells to a memory state (Besides, miRNA-15b did
Figure 4 miRNA-15b regulates phenotypes of CD8+ T cell but does not affect proliferation of T cell. A) After transfected with mimic-15b
or mimic-NC, CD8+ T cells were co-stimulated by CD3/CD28 mAb. The expression of CD69 before or 48 h after co-stimulation was detected by
flow cytometry analysis. The red line represented an isotype-matched control. The blue line represented the staining of CD69 mAb conjugated
with APC. B) The expression of CD44 before or 120 h after co-stimulation was detected by flow cytometry analysis. The red line represented an
isotype-matched control. The blue line represented the staining of CD44 mAb conjugated with PE. C) Before and after co-stimulation by CD3/
CD28 mAb, the positive rates of CD69 (left) or CD44 (right) in CD8+ T cells with mimic-15b or mimic-NC were evaluated. The data were obtained
from three independent experiments (mean ± standard deviation), *P < 0.01. D) CFSE-dilution analysis on CD8+ T cells transfected with mimic-15b
or mimic-NC after 96 h of co-stimulation with CD3/CD28 mAb. Red line represented T cells with mimic-15b and blue line represented T cells
with mimic-NC.







CD28 CD28 molecule activation 1(8mer) 0
TRAF3 TNF receptor-associated factor 3 apoptosis 1(7mer-m8) 3(8mer)
DEDD death effector domain containing apoptosis 1(7mer-m8) 2(7mer-m8, 7mer-1A)
IRAK2 interleukin-1 receptor-associated kinase 2 apoptosis 1(8mer) 0
E2F3 E2F transcription factor 3 proliferation 1(8mer) 1(7mer-m8)
PDCD6IP programmed cell death 6 interacting protein Cell cycle 1(7mer-m8) 1(7mer-m8)
LITAF lipopolysaccharide-induced TNF factor apoptosis 1(7mer-m8) 0
IL-15 Interleukin-15 activation 1(7mer-m8) 0
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Figure 5 (See legend on next page.)
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Figure 5 Prediction and validation of DEDD as target gene of miRNA-15b. A) Schematic representation of miRNA-15b’s sequence bound to
DEDD. B) The luciferase constructs fused to 30UTR (or mut) of DEDD were co-transfected in 293 T cells with mimic-15b or mimic-NC. The
luciferase activities were expressed as mean ± standard deviation (n = 3) of the ratio of firefly luciferase over renilla luciferase (*P < 0.01). C) CD8+ T
cells were isolated from C57BL/6 mice and transfected with mimic-NC or mimic-15b, the levels of DEDD mRNA in T cells with mimic-NC or
mimic-15b were measured by qRT-PCR or PCR electrophoresis (72 h after transfection, * P < 0.05). D) The levels of DEDD protein in CD8+ T cells
with mimic-15b or mimic-NC were assessed by western blot (72 h after transfection, * P < 0.01). E) CD8+ Te and Tm were prepared from the
spleens of C57BL/6 mice with Lewis lung carcinoma. The levels of DEDD protein in CD8+ Te or Tm were assessed by western blot (* P < 0.05).
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while, these data collectively suggest that the regulated
mechanism of miRNA-15b is very complicated.
DEDD is a highly conserved and ubiquitous death ef-
fector domain containing protein. It is widely expressed
in a variety of tissues and induces apoptosis through its
N-terminal DED motif. Bioinformatics analysis and the
luciferase reporter assays revealed that DEDD is a poten-
tial target of miRNA-15b. Transfection with mimic-15b
resulted in a significant reduction in the levels of DEDD
mRNA and protein in T cells, consistent with the anti-
apoptotic effect of miRNA-15b observed in CD8+ T cells
[33]. In addition, our data implied that miRNA-15b may
block the translation of DEDD rather than induce the
degradation of DEDD mRNA, since DEDD mRNA level
was not changed in the Te and Tm cells [34].
In summary, miRNA-15b which was highly expressed
in CD8+ T cells was differentially expressed between Tm
and Te cells in a tumor-burdened environment. It regu-
lated apoptosis of CD8+ T cells by inhibiting the transla-
tion of DEDD and repressed CD8+ T cells activation by
certain pathways (which have not yet been confirmed or
clarified). Increased expression of miRNA-15b in a
tumor-burdened environment could improve anti-
apoptotic ability of CD8+ T cells, but at the same time,
it also greatly compromised anti-tumor effect of T cell
(such as production of IFN-γ) and might cause these T
cells to lose responses to tumors [35]. That is to say,
miRNA-15b which functions in complex molecular net-
works of tumor environment seems to exert negative ef-
fect and be a potential biomarker in special anti-tumor
immunity of CD8+ T cells [36]. The present results pro-
vided a preliminary exploration to improve T cells im-
munotherapy by regulating miRNAs, but further studies
are still needed to confirm and apply related conclusion.Conclusions
miRNA-15b was highly expressed in CD8+ T cells from
tumor-burdened mice. Tm cells expressed higher level of
miRNA-15b than Te cells. Upregulation of miRNA-15b
expression greatly compromise the anti-tumor effect of T
cells from the tumor-burdened mice, although the anti-
apoptotic abilities of CD8+ T cells were enhanced. Our
data suggest that miRNA-15b may play a suppressive rolein the activation of CD8+ T cells and it may be a potential
target for anti-tumor immunotherapy.
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Additional file 1: Table S1. Raw data of miRNA microarray of CD8+ Te
and Tm cells from mice with Lewis lung carcinoma. Complete
information of differential expression of miRNA in CD8+ Te and Tm cells
from tumor-burdened mice was listed in this table.
Additional file 2: Figure S1. Lewis lung carcinoma cells and Tumor-
burdened mice. A) The Lewis lung carcinoma cells in growth logarithm
period. B) Tumor-burdened C57BL/6 mice were raised for 4 weeks until
the lump grew up to 3 × 3 cm.
Additional file 3: Figure S2. Transfection of mimic-miRNA in CD8+ T
cells. A) CD8+ T cells transfected with mimic-NC (left) or mimic-15b-cy3
(right) were imaged by fluorescence microscopy (red sparkle). B)
Representative cytometrical plots showed transfection efficiency of mimic
in CD8+ T cells. Red line represented that T cells were transfected with
mimic-NC, blue line represented that T cells were transfected with
mimic-15b-cy3. C) The relative expression of miRNA-15b was determined
by qRT-PCR in T cells with mimic-NC or mimic-15b. U6 was used as an
internal control to normalize relative amounts of miRNA.
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